Q BioMed Has Licensing Agreement for Generic Bone Metastasis Pain Treatment

Q BioMed Has Licensing Agreement for Generic Bone Metastasis Pain Treatment
Q BioMed has closed an exclusive license and option agreement for Strontium Chloride (SR89), a radiopharmaceutical agent approved by the U.S. Food and Drug Administration for the treatment of pain associated with bone metastasis. The company said it will price the generic drug competitively, and patients will be able to buy it at a lower cost than they are currently paying. SR89 is a radioactive pharmaceutical that provides long-lasting pain relief in patients with painful bone metastasis, typically caused by advanced-stage prostate, lung, or breast cancers. Similar to calcium, it is absorbed preferentially in areas of active bone formation. Primary bone tumors and areas of metastatic involvement are those that accumulate higher levels of the radioactive element. It then emits
Subscribe or to access all post and page content.

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *